Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Enzymatica

Enzymatica

Enzyme-based medical products

Enzymatica is based in Lund, Sweden, and sells medical devices against infectious diseases. The company's first product is ColdZyme® Munspray, which is marketed for cold virus prophylaxis and anti-cold virus therapeutic.

Double-digit sales growth with most markets in the world, including many in Europe, not yet commercialized.

The main risk is that the company might not be able to meet its future liquidity needs. New entrants to the market, changes in regulation governing medical devices, and R&D failures could also impact the long-term outlook.

SEKm 2019 2020e 2021e
Sales 65 120 204
Sales growth (%) 23,5 84,2 70,6
EBITDA -36 -13 31
EBITDA margin (%) -54,8 -10,6 15
EBIT adj -42 -19 25
EBIT adj margin (%) -64 -15,6 12,1
Pretax profit -43 -22 21
EPS rep -0,31 -0,16 0,14
EPS growth (%) 31,5 47,5 189
EPS adj -0,31 -0,16 0,14
DPS 0 0 0
EV/EBITDA (x) -21,1 -59,5 24,3
EV/EBIT adj (x) -18,1 -40,5 30,2
P/E (x) -17,7 -33,7 37,9
P/E adj (x) -17,7 -33,7 37,9
EV/sales (x) 11,6 6,3 3,7
FCF yield (%) -6,6 -4,5 -0,2
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 0,7 1,3 -0,9
SEKm 2019 2020e 2021e
Sales 65 120 204
COGS -19 -40 -74
Gross profit 46 79 130
Other operating items -82 -92 -100
EBITDA -36 -13 31
Depreciation on tangibles -1 -1 -1
Depreciation on intangibles -5 -5 -5
EBITA -42 -19 25
Goodwill impairment charges 0 0 0
Other impairment and amortisation 0 0 0
EBIT -42 -19 25
Other financial items 0 0 0
Net financial items -1 -4 -4
Associated income 0 0 0
Other EO items 0 0 0
Pretax profit -43 -22 21
Tax -1 -1 -1
Net profit -44 -23 20
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders -44 -23 20
EPS -0,31 -0,16 0,14
EPS Adj -0,31 -0,16 0,14
Total extraordinary items after tax 0 0 0
Tax rate (%) 1,8 3 -3
Gross margin (%) 71,3 66,4 63,9
EBITDA margin (%) -54,8 -10,6 15
EBITA margin (%) -64 -15,6 12,1
EBIT margin (%) -64 -15,6 12,1
Pretax margin (%) -66,2 -18,6 10,3
Net margin (%) -67,4 -19,2 10
Growth rates Y/Y 2019 2020 2021
Sales growth (%) 23,5 84,2 70,6
EBITDA growth (%) -2,9 64,3 340,9
EBIT growth (%) -2,4 55 232,1
Net profit growth (%) -2,7 47,5 189
EPS growth (%) 31,5 47,5 189
Profitability 2019 2020 2021
ROE (%) -31,7 -22 19,8
ROE Adj (%) -31,7 -22 19,8
ROCE (%) -28,7 -17 22,7
ROCE Adj(%) -28,7 -17 22,7
ROIC (%) -46,2 -23,3 30,1
ROIC Adj (%) -46,2 -23,3 30,1
Adj earnings numbers 2019 2020 2021
EBITDA Adj -36 -13 31
EBITDA Adj margin (%) -54,8 -10,6 15
EBITA Adj -42 -19 25
EBITA Adj margin (%) -64 -15,6 12,1
EBIT Adj -42 -19 25
EBIT Adj margin (%) -64 -15,6 12,1
Pretax profit Adj -43 -22 21
Net profit Adj -44 -23 20
Net profit to shareholders Adj -44 -23 20
Net Adj margin (%) -67,4 -19,2 10
SEKm 2019 2020e 2021e
EBITDA -36 -13 31
Net financial items -1 -4 -4
Paid tax -1 -1 -1
Non-cash items 0 0 0
Cash flow before change in WC -38 -17 26
Change in WC -3 -7 -12
Operating cash flow -51 -34 1
CAPEX tangible fixed assets -1 -1 -2
CAPEX intangible fixed assets 0 0 0
Acquisitions and disposals 0 0 0
Free cash flow -51 -35 -1
Dividend paid 0 0 0
Share issues and buybacks 0 0 0
Other non cash items 9 28 12
Decrease in net IB debt -42 -7 11
Balance Sheet (SEKm) 2019 2020 2021
Goodwill 63 63 63
Indefinite intangible assets 0 0 0
Definite intangible assets 21 17 14
Tangible fixed assets 5 -15 -13
Other fixed assets 1 1 1
Fixed assets 90 67 65
Inventories 7 13 22
Receivables 16 28 47
Other current assets 2 2 2
Cash and liquid assets 28 21 32
Total assets 144 132 168
Shareholders equity 116 93 113
Minority 0 0 0
Total equity 116 93 113
Long-term debt 4 4 4
Pension debt 0 0 0
Convertible debt 0 0 0
Deferred tax 0 0 0
Other long-term liabilities 0 0 0
Short-term debt 2 2 2
Accounts payable 13 23 40
Other current liabilities 10 10 10
Total liabilities and equity 134 185 144
Net IB debt -24 -17 -28
Net IB debt excl. pension debt -24 -17 -28
Capital invested 91 75 84
Working capital 2 9 21
EV breakdown 2019 2020 2021
Market cap. diluted (m) 774 774 774
Net IB debt Adj -24 -17 -28
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity 0 0 0
EV 750 757 746
Capital efficiency (%) 2019 2020 2021
Total assets turnover (%) 39,5 86,9 136,1
Capital invested turnover (%) 70,9 144,5 256,5
Capital employed turnover (%) 45,3 108,6 187,5
Inventories / sales (%) 9,6 8,1 8,4
Customer advances / sales (%) 13,4 7,3 4,3
Payables / sales (%) 17,6 15 15,4
Working capital / sales (%) 0,1 4,5 7,3
Financial risk and debt service 2019 2020 2021
Net debt / equity (%) -20,5 -18,2 -24,5
Net debt / market cap (%) -5,4 -2,2 -3,6
Equity ratio (%) 80,6 70,7 67,4
Net IB debt adj. / equity (%) -20,5 -18,2 -24,5
Current ratio (%) 222 186,4 202,5
EBITDA / net interest (%) -2537,4 -353,4 851,5
Net IB debt / EBITDA (%) 66,7 133 -90,5
Interest cover (%) -2193 -519,2 685,7
SEKm 2019 2020e 2021e
P/E -17,7 -33,7 37,9
EV/sales 11,56 6,33 3,66
EV/EBITDA -21,1 -59,5 24,3
EV/EBITA -18,1 -40,5 30,2
EV/EBIT -18,1 -40,5 30,2
Dividend yield (%) 0 0 0
FCF yield (%) -6,6 -4,5 -0,2
P/BVPS 6,68 8,33 6,83
P/BVPS Adj 24,69 61,18 21,19
P/E Adj -17,7 -33,7 37,9
EV/EBITDA Adj -21,1 -59,5 24,3
EV/EBITA Adj -18,1 -40,5 30,2
EV/EBIT Adj -18,1 -40,5 30,2
EV/cap. employed 6,2 7,7 6,3
Investment ratios 2019 2020 2021
Capex / sales 1 1 1
Capex / depreciation 10,8 19,8 33,8
Capex tangibles / tangible fixed assets 13,8 -8,1 -15,3
Capex intangibles / definite intangibles 0 0 0
Depreciation on intangibles / definite intangibles 25,5 31,8 39,8
Depreciation on tangibles / tangibles 11,2 -3,5 -4
Shares outstanding adj. 143 143 143
Fully diluted shares Adj 143 143 143
EPS -0,31 -0,16 0,14
Dividend per share Adj 0 0 0
EPS Adj -0,31 -0,16 0,14
BVPS 0,81 0,65 0,79
BVPS Adj 0,22 0,09 0,26
Net IB debt / share -0,2 -0,1 -0,2
Share price 3,08 5,42 5,42
Market cap. (m) 440 774 774
Valuation 2019 2020 2021

Equity research

Read earlier research

Media

Enzymatica - Company presentation with CEO Fredrik Lindberg
Enzymatica - Company presentation with CEO Fredrik Lindberg

Main shareholders - Enzymatica

Main shareholders Share capital % Voting shares % Verified
Mats K Andersson 19.5 % 19.5 % 30 Sep 2019
Danica Pension 17.1 % 17.1 % 31 Dec 2019
Håkan Roos (RoosGruppen) 11.8 % 11.8 % 30 Sep 2019
Björn Nordfors Algkvist 10.5 % 10.5 % 31 Dec 2019
Gudmundur Palmasson 6.6 % 6.6 % 30 Sep 2019
Fortus Hf. 6.3 % 6.3 % 31 Dec 2019
Agusta Gudmundsdottir 4.8 % 4.8 % 30 Sep 2019
AB Possessor 2.1 % 2.1 % 31 Dec 2019
Ulf Wiinberg 1.7 % 1.7 % 31 Dec 2019
Nordnet Pensionsförsäkring 1.7 % 1.7 % 31 Dec 2019
Source: Holdings by Modular Finance AB

Insider list - Enzymatica

Name Quantity Code Date
Gudmundur Palmason +3 574 308 BUY 20 Aug 2019
Gudmundur Palmason -3 574 308 SELL 20 Aug 2019
Ulf Blom - 150 000 SELL 25 Jun 2019
Ulf Blom - 150 000 SELL 19 Jun 2019
Louise Nicolin + 23 000 BUY 18 Jan 2019
Abanico Invest AB -1 958 608 SELL 12 Dec 2018
Abanico Invest AB - 200 000 SELL 12 Dec 2018
Fiddevången Aktiebolag + 50 000 BUY 8 Dec 2018
Mats Kristian Andersson +1 000 000 ALTM 6 Dec 2018
Abanico Invest AB +4 000 000 ALTM 6 Dec 2018

Show More